A northern Kentucky hospital has been selected as the first site for a Phase 2 clinical trial, studying a drug, expected to help patients in the early stages of COVID-19.
Cheri Lawson talked with St. Elizabeth pulmonologist and lead investigator of the study Dr. Chaitanya Mandapakala about the clinical trial and the drug PUL-042. The second phase of the trial was approved by the Food and Drug Administration in early May.
If you appreciate access to this important content during this global health emergency, please help us continue to provide public service journalism and information to Central and Eastern Kentucky communities. Please make your contribution to WEKU today.
